TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
Key Highlights
- ➤CAPTAIN: TULSA patients were over twice as likely to preserve erectile function and pad-free continence
- ➤TULSA complications hospitalization rate was 0.7% versus 6.3% for robotic prostatectomy
- ➤CARE Registry covered 197 patients across five centers with 24-month median follow-up
- ➤Mayo Florida reported 100% pad-free continence and 87.5% preserved erections beyond 12 months
- ➤Siemens 0.55T validation improved thermometry precision 40%, expanding potential platform options
Expert Statements
Mathieu Burtnyk, Chief Technology Officer of Profound Medical
“These presentations illustrate how TULSA’s evidence base is evolving across the dimensions that matter most: meaningful functional outcomes for patients, reproducibility in routine clinical practice, and the potential to extend our technology to a broader range of iMRI platforms”
Mathieu Burtnyk, Chief Technology Officer of Profound Medical
“Together, they reinforce the differentiation of TULSA-PRO and its potential to support broader clinical adoption over time.”
Arun Menawat, Chief Executive Officer and Chairman of Profound Medical
“Our focus is to translate TULSA’s clinical differentiation into a broader opportunity for patients, physicians and healthcare providers,”
Arun Menawat, Chief Executive Officer and Chairman of Profound Medical
“The evidence presented at this year’s iMRI Symposium reinforces the potential of the TULSA Procedure becoming a mainstream treatment modality across the entire prostate disease spectrum, while our technical progress on lower-field-strength Siemens Free.Max points to a potential path toward reducing potential infrastructure barriers to more widespread adoption over time.”
TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO(®) (link) system.
Collectively, the presentations underscore three important dimensions of TULSA’s progress: * Real-world validation: Findings from the CARE Registry and single-center experiences at Mayo Clinic in Florida and Rochester provide complementary evidence of TULSA outcomes across multiple treatment strategies and clinical settings. * Clinical differentiation: Results from the CAPTAIN randomized controlled trial demonstrate statistically superior preservation of erectile function together with pad-free continence with the TULSA Procedure compared with robotic radical prostatectomy (“robotic RP”) at six months. * Platform expansion potential: Technical validation on the Siemens 0.55T Free.Max MRI platform demonstrates the feasibility of delivering TULSA on a lower-field-strength MRI system, potentially broadening equipment options and reducing infrastructure barriers for future TULSA-PRO(®) adoption.* “These presentations illustrate how TULSA’s evidence base is evolving across the dimensions that matter most: meaningful functional outcomes for patients, reproducibility in routine clinical practice, and the potential to extend our technology to a broader range of iMRI platforms,” said Mathieu Burtnyk, Chief Technology Officer of Profound Medical. “Together, they reinforce the differentiation of TULSA-PRO and its potential to support broader clinical adoption over time.”
Get started
Create a free account to read the full story.